Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

NCT02078648 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Adult Brain Glioblastoma
Glioblastoma Multiforme

Interventions

DRUG: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)
DRUG: Bevacizumab
DRUG: SL-701 + GM-CSF
DRUG: Imiquimod

Sponsor

Stemline Therapeutics, Inc.